The percentage is similar to that reported in the UAE, where ER-positive, PR-positive, HER2-positive, and TNBC tumor incidence was 59.3%, 51.0%, 39.1%, and 20.8%, respectively (20). This evidence concerns the gene ERBB2 and neoplasm.